Your browser doesn't support javascript.
loading
Whole-genome landscape of adult T-cell leukemia/lymphoma.
Kogure, Yasunori; Kameda, Takuro; Koya, Junji; Yoshimitsu, Makoto; Nosaka, Kisato; Yasunaga, Jun-Ichirou; Imaizumi, Yoshitaka; Watanabe, Mizuki; Saito, Yuki; Ito, Yuta; McClure, Marni B; Tabata, Mariko; Shingaki, Sumito; Yoshifuji, Kota; Chiba, Kenichi; Okada, Ai; Kakiuchi, Nobuyuki; Nannya, Yasuhito; Kamiunten, Ayako; Tahira, Yuki; Akizuki, Keiichi; Sekine, Masaaki; Shide, Kotaro; Hidaka, Tomonori; Kubuki, Yoko; Kitanaka, Akira; Hidaka, Michihiro; Nakano, Nobuaki; Utsunomiya, Atae; Sica, R Alejandro; Acuna-Villaorduna, Ana; Janakiram, Murali; Shah, Urvi; Ramos, Juan Carlos; Shibata, Tatsuhiro; Takeuchi, Kengo; Takaori-Kondo, Akifumi; Miyazaki, Yasushi; Matsuoka, Masao; Ishitsuka, Kenji; Shiraishi, Yuichi; Miyano, Satoru; Ogawa, Seishi; Ye, B Hilda; Shimoda, Kazuya; Kataoka, Keisuke.
Afiliación
  • Kogure Y; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Kameda T; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Koya J; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Yoshimitsu M; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
  • Nosaka K; Department of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Yasunaga JI; Department of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Imaizumi Y; Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
  • Watanabe M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Saito Y; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Ito Y; Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan.
  • McClure MB; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Tabata M; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Shingaki S; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Yoshifuji K; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Chiba K; Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Okada A; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Kakiuchi N; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Nannya Y; Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Kamiunten A; Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
  • Tahira Y; Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
  • Akizuki K; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Sekine M; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Shide K; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Hidaka T; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Kubuki Y; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Kitanaka A; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Hidaka M; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Nakano N; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Utsunomiya A; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Sica RA; Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.
  • Acuna-Villaorduna A; Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
  • Janakiram M; Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Shah U; Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Ramos JC; Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
  • Shibata T; Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
  • Takeuchi K; Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
  • Takaori-Kondo A; Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
  • Miyazaki Y; Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
  • Matsuoka M; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Ishitsuka K; Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Shiraishi Y; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Miyano S; Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ogawa S; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ye BH; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Shimoda K; Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
  • Kataoka K; Department of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Blood ; 139(7): 967-982, 2022 02 17.
Article en En | MEDLINE | ID: mdl-34695199
ABSTRACT
Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform-specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3'-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell-like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Represoras / Leucemia-Linfoma de Células T del Adulto / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Proteínas Proto-Oncogénicas c-rel / Ataxina-1 / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Represoras / Leucemia-Linfoma de Células T del Adulto / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Proteínas Proto-Oncogénicas c-rel / Ataxina-1 / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article País de afiliación: Japón